While the addition of the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not notably enhance efficacy in advanced HER2-negative GC [110], there are both preclinical [122] and clinical [123] reasons to consider adding pembrolizumab for HER2-positive disease. The gene discussed is PDCD1; the disease is gastric cancer.